New tissue takes up more sugar from blood; hope is that a single injection of tissue could provide long-lasting glucose control, significantly improving quality of life and life expectancy

*note this work will feature in an embargoed press conference at the meeting, see details below*

Injections of genetically engineered muscle tissue hold great promise in treating type 2 diabetes (T2D), the annual meeting of the European Association for the Study of Diabetes in Stockholm, Sweden (19-23 Sept), will hear.

T2D is the most common form of diabetes and is responsible for more than 1 million deaths a year, globally. 

Insulin resistance – where the body’s cells don’t respond properly to insulin and can’t easily take up glucose from blood, causing blood sugar levels to rise – is a key feature of T2D.

Over time, high blood sugar levels can damage the heart, eyes, feet and kidneys and shorten life expectancy by around ten years.

T2D is usually treated with oral medication and lifestyle changes initially but most people will need insulin injections eventually.

To find a better treatment, researchers at Levenberg Lab, Technion – Israel Institute of Technology genetically engineered muscle tissue to take up greater amounts of sugar from the blood.

In previous research, the transplantation of genetically engineered muscle cells into diabetic mice improved their blood sugar levels.1

“A single transplant of engineered tissue kept blood sugar levels lower for four months,” says researcher Ms Hagit Shoyhet. 

In their latest research, the team used the same technique to genetically modify human muscle cells.  The cells were engineered to make more insulin-activated sugar transporter (GLUT4), a protein that’s known to help cells take in sugar.

The cells were then grown into 3D tissue in the lab on scaffolds – matrices made from a biopolymer.

Tests showed that the new tissue was able to take up 50% more sugar than normal muscle tissue.

Pieces of tissue 6mm in diameter were then transplanted into diabetic mice through a small incision in the abdomen and their blood glucose levels were monitored.

The transplant resulted in a reduction in blood glucose levels of around 20%.

The team also developed a more flexible, sponge-like scaffold that could be injected using a syringe, removing the need for surgery.

The tissue grown on the new scaffold developed normally.  Tests showed that injection did not cause significant damage to the tissue grown on the new scaffold and that the tissue could still take up sugar from the blood.

Ms Shoyhet says: “New treatments for type 2 diabetes are urgently needed. Our technique would allow a patient’s own cells to be modified to take up more glucose.

“Preliminary results indicate the approach has great potential and, in the future, a single injection of engineered tissue could provide long-lasting glucose control, significantly improving quality of life and life expectancy.”

The researchers have more pre-clinical work planned and hope to start clinical trials soon.

Ms Hagit Shoyhet, Levenberg lab, Department of Biomedical Engineering and Schneur Center for Diabetes Research, Technion – Israel Institute of Technology, Haifa, Israel. T) +972 542180989 E) Hagit.sh@campus.technion.ac.il

Alternative contact: Tony Kirby in the EASD Media Centre. T) +44 7834 385827 E) tony@tonykirby.com

1. https://www.science.org/doi/full/10.1126/sciadv.abg3947

The authors declare no conflicts of interest.

This press release is based on oral presentation 196 at the annual meeting of the European Association for the Study of Diabetes (EASD). The material has been peer reviewed by the congress selection committee. There is no full paper at this stage and, as it is an oral presentation, no poster is available.

The authors declare no conflict of interest

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Judy Naylor Diabetologia diabetologia-j@bristol.ac.uk Office: 44-117-323-5338

Ms Hagit Shoyhet Levenberg lab, Department of Biomedical Engineering and Schneur Center for Diabetes Research, Technion – Israel Institute of Technology, Haifa, Israel. Hagit.sh@campus.technion.ac.il Cell: +972 542180989

Tony Kirby EASD Media Centre tony.kirby@tonykirby.com Cell: +44 7834 385827

Copyright © 2022 by the American Association for the Advancement of Science (AAAS)

Copyright © 2022 by the American Association for the Advancement of Science (AAAS)